Technical Analysis for GPCR - Structure Therapeutics Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Jack-in-the-Box Bearish | Bearish Swing Setup | 0.00% | |
| Pocket Pivot | Bullish Swing Setup | 0.00% | |
| Stochastic Reached Oversold | Weakness | 0.00% | |
| Inside Day | Range Contraction | 0.00% | |
| Gapped Up | Strength | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| 20 DMA Resistance | Bearish | 1.30% | |
| MACD Bearish Signal Line Cross | Bearish | 1.30% | |
| Expansion Breakdown | Bearish Swing Setup | 1.30% | |
| Reversal New Lows Setup | Bearish Swing Setup | 1.30% |
| Alert | Time |
|---|---|
| Possible Inside Day | 1 day ago |
| 10 DMA Resistance | 1 day ago |
| 3x Volume Pace | 1 day ago |
| Up 5% | 1 day ago |
| Up 1 ATR | 1 day ago |
Get this analysis on your stocks daily!
- Earnings date: 05/09/2024
Structure Therapeutics Inc. Description
Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. The company is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist, targeting apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension; and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was founded in 2016 and is headquartered in South San Francisco, California.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Life Sciences Biology Molecular Biology Obesity Signal Transduction Idiopathic Pulmonary Fibrosis Pulmonary Arterial Hypertension Chronic Disease Diabetes Mellitus Biochemistry Glucagon
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 75.0167 |
| 52 Week Low | 25.57 |
| Average Volume | 525,193 |
| 200-Day Moving Average | 44.30 |
| 50-Day Moving Average | 38.59 |
| 20-Day Moving Average | 36.82 |
| 10-Day Moving Average | 36.08 |
| Average True Range | 2.28 |
| RSI (14) | 36.71 |
| ADX | 13.61 |
| +DI | 12.72 |
| -DI | 17.85 |
| Chandelier Exit (Long, 3 ATRs) | 34.83 |
| Chandelier Exit (Short, 3 ATRs) | 40.57 |
| Upper Bollinger Bands | 40.17 |
| Lower Bollinger Band | 33.47 |
| Percent B (%b) | 0.11 |
| BandWidth | 18.20 |
| MACD Line | -0.87 |
| MACD Signal Line | -0.70 |
| MACD Histogram | -0.171 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 37.92 | ||||
| Resistance 3 (R3) | 38.19 | 37.22 | 37.30 | ||
| Resistance 2 (R2) | 37.22 | 36.27 | 37.09 | 37.09 | |
| Resistance 1 (R1) | 35.71 | 35.69 | 35.23 | 35.44 | 36.89 |
| Pivot Point | 34.74 | 34.74 | 34.50 | 34.61 | 34.74 |
| Support 1 (S1) | 33.23 | 33.79 | 32.75 | 32.96 | 31.51 |
| Support 2 (S2) | 32.26 | 33.21 | 32.13 | 31.31 | |
| Support 3 (S3) | 30.75 | 32.26 | 31.10 | ||
| Support 4 (S4) | 30.48 |
